Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Keeping pressure on Amgen, Mirati draws mixed reviews on latest cut of KRAS data
4 years ago
Roche's CD20xCD3 doesn't beat Genmab at ORR, but sets bar for CR data on lymphoma drug
4 years ago
Pharma
In search of elusive NASH breakthrough, Pfizer spotlights combo approach
4 years ago
Saying goodbye to R&D chief, Flagship-backed Axcella drops PhII program as it focuses on long Covid, NASH
4 years ago
People
Coronavirus
Planning ahead for crowded ulcerative colitis market, Pfizer spells out PhIII data on $6.7B Arena drug
4 years ago
Pfizer spinout SpringWorks will ship its first drug to the FDA before year’s end with PhIII win
4 years ago
A new era of treatment: How biomarkers are changing the way we think about cancer
4 years ago
In Focus
Blaming Covid disruption, supply shortages, microcap biotech hits the brakes on cell therapy trial
4 years ago
Cell/Gene Tx
Lilly's mirikizumab, once a contender for psoriasis, bolsters case for UC indication in maintenance trial data readout
4 years ago
Pharma
Idorsia claims PhIII win for hypertension drug at center of $230M J&J deal
4 years ago
'Xenotransplantation is coming': New NEJM paper gives detailed look into 2 pig-to-human kidney transplant cases
4 years ago
One trial down, one to go as Concert Pharmaceuticals tunes up PhIII win for alopecia drug
4 years ago
Fresh off $11.6B sale to Pfizer, New Biohaven hits Phase III setback just weeks after Vlad Coric chalked up promise
4 years ago
Ahead of FDA, EMA recommends authorizing new gene therapy treatment for ultra-rare disease
4 years ago
Cell/Gene Tx
Athersys tries to post-hoc-analyze its way out of another trial fail for stroke stem cell therapy
4 years ago
Cell/Gene Tx
Trying to shake up the Parkinson's paradigm, AbbVie submits NDA for continuous, 24-hour infusion therapy
4 years ago
FDA+
Touting 100% OS rate in pivotal rare disease trial, Rocket Pharma ready to head to FDA
4 years ago
Cell/Gene Tx
Flagship's Foghorn, partnered with Merck and Eli Lilly, gets a partial FDA hold after patient death
4 years ago
FDA+
Bayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death
4 years ago
Deals
A year after scoring FDA approval for diabetes drug, Zealand touts positive PhIII data for new indication
4 years ago
NIH grants over $500M to create antivirals for future pandemics
4 years ago
Another biotech that went public in pandemic boom aims to weather the bear market through R&D cutbacks
4 years ago
People
Going for broke, Tricida is slamming the brakes on a pivotal trial early while planning a run at the FDA
4 years ago
As Big Pharma circles RSV wagons, biotech reports mid-stage flop for its antiviral
4 years ago
First page
Previous page
134
135
136
137
138
139
140
Next page
Last page